TRPV4 and heart failure: Similarly, another single-center study designed to estimate the effects of GSK2798745, a novel TRPV4 inhibitor, on pulmonary gas exchange and pulmonary function in participants with heart failure has already completed a phase 2 clinical trial (GlaxoSmithKline, 2018).